IDSA przegrala z Blumenthalem

01.05.08, 22:10
FOR IMMEDIATE RELEASE May 1, 2008

CONTACT:
Nicole Rodgers 202-822-5200

Settlement Announced in Landmark Investigation of Lyme Disease
Diagnosis and Treatment Guidelines

Patients' Rights Groups Applaud Connecticut Attorney General
Blumenthal's Settlement in Anti-trust Case Against Powerful Medical
Society


Hartford, CT - Patients' rights groups today hailed Connecticut
Attorney
General Blumenthal's announcement of a settlement in a landmark
antitrust investigation into the Lyme treatment guidelines of the
Infectious Diseases Society of America (IDSA).

"My office uncovered undisclosed financial interests held by several
of the most powerful IDSA panelists," said Blumenthal. "The IDSA's
guideline panel improperly ignored, or minimized, consideration of
alternative medical opinion and evidence regarding chronic Lyme
disease, potentially raising serious questions about whether the
recommendations reflected all relevant science."

The groundbreaking settlement announced today forces a complete
review of the IDSA guidelines by a new panel free from conflicts of
interest, specifically excluding previous panel members. This panel
will consider a range of scientific evidence in a public forum
broadcast live over the internet and will be overseen by a
specialist
in financial conflicts of interest in medicine.

"This settlement makes it clear that the IDSA guideline development
process was corrupted by a commercially driven panel that excluded
evidence supporting longer term treatment of Lyme disease," said
attorney Lorraine Johnson, Executive Director of the California Lyme
Disease Association (CALDA). "This settlement allows suppressed
scientific viewpoints and evidence to be heard, and it is promising
news for patients."

This is the first-ever antitrust investigation against a medical
society's guidelines development process.

"We congratulate Attorney General Blumenthal for exposing the IDSA's
conflicts of interest and helping reduce the suffering of Lyme
patients everywhere," said Pat Smith, president of the national Lyme
Disease Association (LDA). "The IDSA guidelines are dangerous for
patients who suffer longer-term Lyme symptoms that do not fall
within
the IDSA's narrow disease definition."

The IDSA guidelines are treated as mandatory within the medical
community. More than 50 physicians who use longer-term treatment
approaches have been investigated or sanctioned by state medical
boards. The guidelines can also result in financial problems for
patients, since insurance companies refuse to reimburse for longer-
term treatment and pharmacies may refuse to fill prescriptions.

The majority of individuals involved in the IDSA guidelines
development process held direct or indirect commercial interests
related to Lyme vaccines, patents, and/or test kits, and did not
take
the opinions or experiences of the competing Lyme groups into
account.
While the announcement of a settlement comes as a huge relief to
suffering Lyme patients, the case has much broader implications for
a
health care system that often contends with conflicts-of- interest
in
guideline processes - guidelines which are often used by insurance
companies to limit diagnosis and treatment options.

"Today's settlement marks an important victory for all patients who
suffer Lyme disease, but it is also a victory for anyone concerned
about health care," said Johnson. "Commercially driven guidelines
that limit patient treatment options are a major issue today in
healthcare, and this decision marks an important step towards
addressing it."

The national Lyme Disease Association, (LDA), CALDA, and Time for
Lyme are non-profit organizations that were founded by individuals
who had personal experience with Lyme disease, in order to address
the lack of education and support services available for this newly
emerging infection.

# # #
    • franiolek1 Re: IDSA przegrala z Blumenthalem 01.05.08, 22:15
      Nowe osoby maja byc mianowane w IDSA do zredagowania nowych
      wskazowek o leczeniu boreliozy!!!
      Zostalo ustalone, ze wskazowki IDSA byly dyktowane przez profity
      komercjalne, dowiedziono korupcje.
      To jest ewenement w swiecie medycznym.
      Wielki dzien dla pacjentow chorych na borelioze!!!!!!!!!!!!!
      • grizac Re: IDSA przegrala z Blumenthalem 01.05.08, 22:36
        Co to oznacza dla nas?
        Wytyczne dotyczące leczenia bb w Polsce kopiowane ze wskazówek IDSA powinny
        trafić do kosza. I to jak najszybciej.
        • franiolek1 Re: IDSA przegrala z Blumenthalem 01.05.08, 22:41
          Wszystkie wskazowki europejskie sa pisane na podstawie wskazowek
          IDSA. Dzisiaj wrzucono wskazowki IDSA do smieci, czyli europejskie
          wskazowki tez polecialy.
          Nowa ekipa, nie skorumpowana, bedize pisac nowe wskazowki - jezeli
          napisza cos sensownego, to zycie chorych na choroby odkleszczowe
          moze sie diametralnie zmienic. To rowniez pobudzi naukowcow i
          otworzy droge tym ktorzy juz cos w tej dziedzinie odkryli i
          wiedzieli....
          Wielki dzien, naprawde.
      • borelka46 Re: IDSA przegrala z Blumenthalem 01.05.08, 22:39
        Franiolku, całuje Cię w twoje stópki!!!!!
        A więc godzina 0 wybiła, teraz to się będzie działo.
        I w poniedziałek,u Alicji Resich -Modlińskiej będzie pierwsza wiadomość na ten
        temat, oczywiście od naszego stowarzyszenia.
        Franiolkuuuuu,brak mi słów.
        • stachenka Re: IDSA przegrala z Blumenthalem 01.05.08, 23:39
          > I w poniedziałek,u Alicji Resich -Modlińskiej będzie pierwsza wiadomość na ten
          > temat,

          Borelko, o co chodzi z tą Resich-Modlińską? Ona coś w TV prowadzi czy jak? Co?
          Gdzie? Kiedy?
          • borelka46 Re: IDSA przegrala z Blumenthalem 02.05.08, 12:16
            Stachenka poszukaj gdzieś na forum jest nawet link do zapowiedzi tego programu
            -8 rano TVP2 Resich będzie o BB z naszym stowarzyszeniem - to jakiś śniadaniowy
            program ale dziennikarz wysokiej klasy.
            Co do odpowiedzi Idsa - to i tak uważam że to już godz. 0 i szampana możemy
            otwierac.
            Teraz już z górki!
    • klematis7 Re: IDSA przegrala z Blumenthalem 01.05.08, 22:39
      no wreszcie ktos zmadrzal albo przejrzal na oczy. Bo myslalam juz,
      ze dobro ze zlem wygrywa tylko w filmachsmile
      • franiolek1 Re: IDSA przegrala z Blumenthalem 02.05.08, 11:29
        IDSA oddaje cios....

        Agreement Ends Lyme Disease Investigation By Connecticut Attorney
        General

        Medical Validity of IDSA Guidelines Not Challenged

        The Infectious Diseases Society of America (IDSA) has entered into
        an agreement with the Attorney General of Connecticut ending his
        investigation of the Society's Lyme disease guidelines. Under the
        agreement, the guidelines remain in effect; but in an effort to
        clear the air, IDSA is voluntarily agreeing to an extra step: a one-
        time special review of the Lyme disease guidelines.

        The agreement ends the investigation of IDSA and its volunteer
        guideline panel members without the filing of a complaint or the
        entry by a court of factual or legal findings, without IDSA paying
        any fines or penalties, and without imposing on IDSA any
        restrictions on its right to promulgate guidelines for Lyme disease
        or any other disease or condition in the manner it believes best
        serves public health.

        "IDSA has agreed to this unique, singular review of our guidelines
        because the panel will consist solely of physicians and scientists,"
        said IDSA President Donald Poretz, MD. "We are confident that our
        guidelines for the diagnosis and treatment of Lyme disease represent
        the best advice that medicine currently has to offer, as is the case
        with all of the medical guidelines issued by the Society, and we
        look forward to the opportunity to put to rest any questions about
        them."

        The IDSA Lyme disease guidelines recommend against long-term
        antibiotic therapy, an unproven and potentially dangerous treatment.
        A small group of physicians outside the medical mainstream and their
        patients endorse such long-term treatment, despite the compelling
        medical evidence that it is ineffective and can have serious, life-
        threatening complications— and, furthermore, is extremely expensive.
        This agreement does not change the medical advice to patients: The
        2006 Lyme disease guidelines remain in place.

        Under the terms of the agreement announced today, IDSA will convene
        a review panel to conduct a comprehensive review of the Lyme-related
        literature to determine whether the 2006 guidelines should be
        revised or updated. While IDSA periodically reviews all of its
        treatment guidelines in order to keep them current, the agreement
        allows for an expanded process that includes an opportunity for
        public presentation and submission of information to ensure that all
        points of view are presented to and considered by the review panel.

        IDSA is voluntarily agreeing to this extra scrutiny in the hope that
        it will help put to rest assertions that have been made – all of
        them unfounded – that IDSA has ignored divergent opinions in
        developing its Lyme disease guidelines. This expanded review process
        is pertinent to this unique case only. IDSA has not agreed to use it
        as a model for other IDSA guidelines, nor is IDSA urging other
        medical organizations and societies to use it.

        The main actions of the agreement include:

        Complete resolution of the Attorney General's investigations,
        issues, and potential claims and causes of action against IDSA and
        its volunteer panel members.
        The current Lyme disease guidelines remain in effect. The medical
        and scientific basis of the 2006 guidelines remains in place and
        unchallenged.
        IDSA will convene a review panel to determine whether the 2006 Lyme
        disease guidelines should be revised or updated. Howard Brody, MD,
        PhD, who has been jointly selected by the Office of the Attorney
        General and IDSA, will serve as an ombudsman who will have a limited
        role that will focus on screening potential conflicts of interest.
        The ombudsman will not be involved in the operation of the review
        panel. Any proposed changes to the guidelines would require a
        supermajority vote of 75 percent of the panel.
        IDSA strongly disagrees with the Attorney General's assertion that
        panel members had significant conflicts of interest. Panel members
        had no financial interests that would have affected, or been
        affected by, recommendations in the guidelines. The guidelines
        recommend generic drugs and generic diagnostic tests. Panel members
        do not stand to profit from any recommendation in the guidelines. In
        fact, the panel members denied themselves and their colleagues an
        opportunity to generate a significant amount of revenue when they
        recommended against expensive, repeated, long-term antibiotic
        therapy.

        IDSA also strongly disagrees with the Attorney General's allegation
        that the Lyme disease guideline panel excluded competing viewpoints.
        In fact, the panel offered an opportunity for other organizations
        and individuals to submit additional evidence and carefully
        considered all information provided. In 2000, a single member of the
        panel voluntarily stopped participating. He was not removed from the
        panel, as the Attorney General has alleged. Furthermore, all IDSA
        guidelines are subjected to a rigorous, multi-level review and
        approval process before they are published, which allows other
        clinicians who did not serve on the panel that developed the
        guidelines to ensure that the guidelines are relevant, accurate,
        useable, and balanced.

        IDSA's guidelines—like all medical societies' guidelines—are
        voluntary. They are for the benefit of physicians seeking the best
        possible advice from experts in the field. Medical societies do not
        have the authority or the desire to dictate to physicians how to
        practice medicine.. Nor do they have the ability to dictate to
        insurance companies how to reimburse for services. No ties exist
        between IDSA and any insurance company.

        The physicians who wrote IDSA's 2006 guidelines concluded that, for
        nearly all patients, a short course of antibiotics is an effective
        treatment for Lyme disease. Studies have proven that long-term
        antibiotic treatment, which is usually given through a needle and a
        catheter, is ineffective, expensive, and potentially harmful. The
        overuse of antibiotics also contributes to an important public
        health threat: the development of drug-resistant infections that are
        difficult if not impossible to treat.

        "We recognize that medicine is always evolving, and we welcome the
        opportunity that the review panel provides to examine any new
        evidence and vet our earlier findings," said Dr. Poretz. "We are
        pleased that under this agreement, the proper diagnosis and
        treatment for Lyme disease will be decided in a medical forum, not a
        courtroom. We hope this special review of the guidelines will help
        quell the unfortunate controversy surrounding the treatment of Lyme
        disease and ensure that patients receive advice and treatment based
        on the best available scientific and medical evidence."

        ###

        IDSA is an organization of physicians, scientists, and other health
        care professionals dedicated to promoting health through excellence
        in infectious diseases research, education, prevention, and patient
        care. The Society, which has more than 8,000 members, was founded in
        1963 and is based in Arlington, VA. For more information, visit
        www.idsociety. org.
        • franiolek1 Re: IDSA przegrala z Blumenthalem 02.05.08, 11:31
          Tak jak mowil Artur: to nie jest wygrana wojna, ale wygrana bitwa.
          Trzeba poczekac i zobaczyc, co z tego wyniknie....trzeba poczekac na
          nowe wytyczne i dopiero wtedy, ewentualnie, otwierac szampany (
          bezalkoholowe).
          • borelka46 Re: IDSA przegrala z Blumenthalem 02.05.08, 12:20
            Franiolek pare słów po polsku dla tych co nie wykumają tej odpowiedzi.
            Na forum mamy wielu niejęzycznych,musimy o tym pamiętać.
            A Ja i tak szampana już otworzę!
    • zazule Re: IDSA przegrala z Blumenthalem 02.05.08, 12:53
      O to za rok I Maja mozemy zorganizowac sobie pochód z tego powodu bo
      to moze bedzie przełomowa data dla chorych na LD.
      pozdr
      zaz
    • tadeusz998 Re: IDSA przegrala z Blumenthalem 02.05.08, 14:18
      Nie znam angielskiego ,ale mam translator .Jest to trochę śmieszne tłumaczenie ,
      jednak można zrozumieć sens .
      Mam trochę oporów , ale może komuś się przyda .

      DLA NATYCHMIASTOWE WYPUSZCZENIE May 1, 2008

      KONTAKT:
      Nicole Rodgers 202-822-5200

      Osada Announced w Investigation Landmark Lyme Disease
      Diagnoza i Guidelines Treatment

      Groups Rights pacjentów Applaud prokuratora generalnego Connecticut
      Settlement Blumenthal w Anti zaufanie Case Against Powerful Medical
      Społeczeństwo


      Hartford, CT - prawa Patients grupuje dzisiaj przybyły Connecticut
      Adwokat
      Ogłoszenie ogólnego Blumenthal osady w słupie granicznym
      antymonopolowe śledztwo do wskazówki traktowania Lyme
      Society chorób zakaźnych America (IDSA).

      "Moje biuro odkryło nieujawnione finansowe zainteresowania obstawane przy kilku
      najpotężniejszego panelists IDSA," powiedział Blumenthal. "IDSA
      panel guideline nieodpowiednio zignorował, albo pomniejszył, rozważanie z
      alternatywna medyczna opinia i dowód dotyczący chronicznego Lyme
      choroba, potencjalnie podnosząc poważne pytania około czy
      polecenia odbijały wszystką związaną naukę."

      Osada rozpoczęcia wykopów zawiadomiła dzisiaj zmusza kompletnego
      recenzja wskazówki IDSA przez nowy panel wolny od konfliktów z
      zainteresowanie, szczególnie wykluczając poprzednich członków panelu. Ten panel
      rozważą zasięg naukowego dowodu w publicznym forum
      transmisja żyją przez internet i są doglądnięty przez
      specjalista
      w finansowych konfliktach zainteresowania medycyną.

      "Ta osada robi to przejaśnia się, że rozwój guideline IDSA
      proces został skorumpowany przez komercyjnie jedzie panel który wyłączył
      dowód popierający dłuższe leczenie okresu choroby Lyme," powiedział
      adwokat Lorraine Johnson, Executive Director California Lyme
      Association choroby (CALDA). "Ta osada pozwala zniesiony
      naukowe punkty widzenia i dowód, by zostać usłyszany i to jest obiecujące
      wiadomość dla pacjentów."

      To jest pierwszy kiedykolwiek antymonopolowe śledztwo przeciw medycznemu
      proces rozwoju wskazówki społeczeństwa.

      "Gratulujemy prokuratora generalnego Blumenthal, ponieważ wystawiając IDSA
      konflikty zainteresowania i pomagając zmniejszają cierpienie Lyme
      pacjenci wszędzie," powiedział Pat Smith, prezydent narodowego Lyme
      Association choroby (LDA). "Wskazówki IDSA są niebezpieczny dla
      okres symptomy Lyme pacjenci, którzy cierpią dłużej, które nie spadają
      w
      wąska definicja choroby IDSA."

      Wskazówki IDSA jest potraktowany jako obowiązkowy w medycznym
      społeczność. Więcej niż 50 lekarzy, którzy używają dłużej - traktowanie okresu
      podejścia zostały zbadane albo zostały usankcjonowane około państwowy medyczny
      deski. Wskazówka może też skończyć się finansowymi problemami dla
      pacjenci, odkąd przedsiębiorstwa ubezpieczeniowe odmawiają zrefundować dla dłużej -
      traktowanie okresu i apteki mogą odmówić napełnić recepty.

      Większość osób włączyła w wskazówce IDSA
      proces rozwoju trzymał bezpośrednie albo pośrednie handlowe zainteresowania
      wiązał się z Lyme szczepionki, patenty i / albo ekwipunki próby i nie zrobił
      weź
      opinie albo doświadczenia rywalizujących grup Lyme do
      rachunek.
      Kiedy ogłoszenie osady przychodzi jako ogromna ulga
      cierpiąc pacjentów Lyme, przypadek ma obszerne implikacje dla
      a
      system opieki zdrowotnej ten często walczy z konfliktami
      • borelka46 Re: IDSA przegrala z Blumenthalem 02.05.08, 15:06
        Tadzik też Cię całuje w stópki, uśmiałam się setnie.No i mam pojęcie o co tam
        biega.
        Smiejcie się ludziska ,bo to radość dla nas wielka.
    • stachenka Re: IDSA przegrala z Blumenthalem 14.08.08, 15:35
      w górę... serca wink
      • dx771 Re: IDSA przegrala z Blumenthalem 06.09.08, 10:46
        .
Inne wątki na temat:
Pełna wersja